Skip to main content

Table 3 Variables associated with QFT-GIT reversion

From: Serial interferon-gamma release assays during treatment of active tuberculosis in young adults

  Number (%) Number with reversion (%) Odds ratio (95%CI) Pvalue
Cavity     
   Present 18 (31.6) 6 (33.3) 1.00 (reference) 0.85
   Absent 39 (68.4) 12 (30.8) 1.13 (0.34-3.71)  
Lesion extent     
   > one lobe 28 (49.1) 8 (27.6) 1.00 (reference) 0.45
   one lobe 29 (50.9) 10 (35.7) 1.55 (0.50-4.77)  
Pleural effusion     
   Absent 43 (75.4) 11 (25.6) 1.00 (reference) 0.10
   Present 14 (24.6) 7 (50.0) 2.91 (0.83-10.17)  
CRP     
   < 3 mg/dl 41 (73.3) 10 (24.4) 1.00 (reference) 0.046
   ≥ 3 mg/dl 15 (26.8) 8 (53.3) 3.54 (1.03-12.24)  
Body temperature*     
   < 38.3°C 44 (76.8) 11 (25.6) 1.00 (reference) 0.056
   ≥ 38.3 °C 13 (23.2) 7 (53.8) 3.50 (0.97-12.67)  
Baseline QFT-GIT     
   decrease by 1 IU/ml 57 (100) 18 (31.6) 1.24 (1.03-1.49) 0.03
  1. All analysis was performed with exclusion of two participants with initial negative QFT.
  2. *Peak body temperature within 24 hours of initial hospital visit.
  3. QFT-GIT, QuantiFERON-TB gold in-tube assay; CRP, C-reactive protein.